Design of a beam shaping assembly and preliminary modelling of a treatment room for accelerator-based BNCT at CNEA

Using ANN for thermal neutron shield designing for BNCT treatment room

Occupational radiation protection should be applied to the design of treatment rooms for various radiation therapy techniques, including BNCT, where escaping particles from the beam port of the beam shaping assembly (BSA) may reach the walls or penetrate through the entrance door. The focus of the present study is to design an alternative shielding material, other than the conventional material of lead, that can be considered as the material used in the door and be able to effectively absorb the BSA neutrons which have slowed down to the thermal energy range of < 1 eV after passing through the walls and the maze of the room. To this aim, a thermal neutron shield, composed of polymer composite and polyethylene, has been simulated using the Geant4 Monte Carlo code. The neutron flux and dose values were predicted using an artificial neural network (ANN), eliminating the need for time-consuming Monte Carlo simulations in all possible suggestions. Additionally, this technique enables simultaneous optimization of the parameters involved, which is more effective than the traditional sequential and separate optimization process. The results indicated that the optimized shielding material, chosen through ANN calculations that determined the appropriate thickness and weight percent of its compositions, can decrease the dose behind the door to lower than the allowable limit for occupational exposure. The stability of ANN was tested by considering uncertainties with the Gaussian distributions of random numbers to the testing data. The results are promising as they indicate that ANNs could be used as a reliable tool for accurately predicting the dosimetric results, providing a drastically powerful alternative approach to the time-consuming Monte Carlo simulations.

Gamma-ray and neutron shielding features for some fast neutron moderators of interest in 252Cf-based boron neutron capture therapy

Monte Carlo simulations (MCNP) were carried out to model suitable ²⁵²Cf-based gamma transmission and neutron attenuation geometries to evaluate the gamma-ray shielding features and neutron attenuation capabilities for Al₂O₃, MgF₂, Fluental and AlF₃, as fast neutron moderators of potential interest in ²⁵²Cf-based Born Neutron Capture Therapy (BNCT) facilities. The mass attenuation coefficient (μ/ρ), Half-Value Layer (HVL), Mean Free Path (MFP) and gamma transmission factor (I/I_o) for Al₂O₃, MgF₂, Fluental and AlF₃ were simulated at gamma energies, 0.3 MeV, 0.364 MeV, 0.662 MeV, 1.25 MeV and 7.12 MeV. The MCNP simulated μ/ρ values were compared to theoretical XCOM values and good agreement was observed. The ratio of total thermal neutron flux to the total fast neutron flux (φ _{total thermal}/φ _{total fast}) and the total flux of gamma rays (φ _{total (n,γ) gamma}) resulting from thermal neutron capture (n,γ) reactions, were simulated and compared as a function of thickness for the four sample moderators. The values of the effective fast neutron removal cross section Σ_R (cm^-1) for the four sample moderators were calculated and compared.

Radiation shielding design of BNCT treatment room for D-T neutron source

Recent studies have shown that D-T neutron generator can be used as a proper neutron source for Boron Neutron Capture Therapy (BNCT) of deep-seated brain tumors. In this paper, radiation shielding calculations have been conducted based on the computational method for designing a BNCT treatment room for a recent proposed D-T neutron source. By using the MCNP-4C code, the geometry of the treatment room has been designed and optimized in such a way that the equivalent dose rate out of the treatment room to be less than 0.5μSv/h for uncontrolled areas. The treatment room contains walls, monitoring window, maze and entrance door. According to the radiation protection viewpoint, dose rate results of out of the proposed room showed that using D-T neutron source for BNCT is safe.

Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT)

The first BNCT trials took place in the USA in the early 1960's, yet BNCT is still far from mainstream medicine. Nonetheless, in recent years, reported results in the treatment of head and neck cancer and recurrent glioma, coupled with the progress in developing linear accelerators specifically for BNCT applications, have given some optimism to the future of BNCT. This article provides a brief reminder on the ups and downs of the history of BNCT and supports the view that controlled and prospective clinical trials with a modern design will make BNCT an evidence-based treatment modality within the coming decade.

Evaluation of performance of an accelerator-based BNCT facility for the treatment of different tumor targets

PURPOSE

Encouraging Boron Neutron Capture Therapy (BNCT) clinical results obtained in recent years have stimulated intense research to develop accelerator-based neutron sources to be installed in clinical facilities. In this work an assessment of an accelerator-based BNCT facility for the treatment of different tumor targets was performed, comparing the accelerator-derived results with reported reactor-based trials under similar conditions and subjected to the same clinical protocols.

MATERIALS AND METHODS

A set of real image studies was used to cover clinical-like cases of brain and head-and-neck tumors. In addition, two clinical cases of malignant nodular melanoma treated at the RA-6 BNCT facility in Argentina were used to thoroughly compare the clinical dosimetry with the accelerator-derived results.

RESULTS

The minimum weighted dose delivered to the clinical target volume was higher than 30 Gy and 14 Gy for the brain tumor and head-and-neck cases, respectively, in agreement with those achieved in clinical applications. For the melanoma cases, the minimum tumor doses were equal or higher than those achieved with the RA-6 reactor for identical field orientation and protocol. The whole-body dose assessment showed that the maximum photon-equivalent doses for those normal organs close to the beam direction were below the upper limits considered in the protocols used in the present work.

CONCLUSIONS

The obtained results indicate not only the good performance of the proposed beam shaping assembly design associated to the facility but also the potential applicability of accelerator-based BNCT in the treatment of both superficial and deep-seated tumors.